Alto Neuroscience, Inc.

ANRO

Healthcare|Biotechnology|US

$25.16

+3.29 (+15.04%)

DCF Value

$5.91

Tangible Book / Share

$5.12

Cash / Share

$5.69

Clinical Trials (12)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06502964 Study of ALTO-101 in Patients With Schizophrenia	Schizophrenia, Cognitive Impairment	P2	Recruiting	82	RCT, Double-blind	ALTO-101, Placebo
NCT05922878 Study of ALTO-300 in MDD	Major Depressive Disorder	P2	Recruiting	325	RCT, Double-blind	ALTO-300, Placebo
NCT06656416 ALTO-100 in Bipolar Disorder With Depression (BD-D)	Bipolar Disorder I or II With a Major Depressive Episode	P2	Recruiting	200	RCT, Double-blind	ALTO-100, Placebo
NCT07553637 ALTO-207 in Adults With Treatment-resistant Depression (TRD)	Treatment-resistant Depression (TRD)	P2	Recruiting	178	RCT, Double-blind	ALTO-207, Placebo
NCT04388189 Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion	Major Depressive Disorder	P4	Withdrawn	—	RCT, Open-label	Duloxetine, Bupropion
NCT04388202 Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram	Major Depressive Disorder	P4	Withdrawn	—	RCT, Open-label	Sertraline, Escitalopram
NCT05118750 ALTO-300 in Depression	Major Depressive Disorder	P2	Completed	91	Open-label	ALTO-300 oral (PO) tablet
NCT05419869 Pilot Decentralized Trial	Major Depressive Disorder	P2	Completed	21	Open-label	ALTO-100 PO Tablet
NCT05157945 ALTO-300 in Depression (ALTO-300-004)	Major Depressive Disorder	P2	Completed	148	Open-label	ALTO-300 PO Tablet
NCT05117632 ALTO-100 in MDD and/or PTSD	Major Depressive Disorder, Post Traumatic Stress Disorder	P2	Completed	245	Open-label	ALTO-100 PO tablet
NCT05712187 Phase 2b Study of ALTO-100 in MDD	Major Depressive Disorder	P2	Completed	301	RCT, Double-blind	ALTO-100, Placebo
NCT06391593 PD, PK, and Safety of ALTO-203 in Patients With MDD	Major Depressive Disorder, Anhedonia	P2	Completed	69	RCT, Double-blind	ALTO-203 25 μg, ALTO-203 75 μg, Placebo